- Home
- PRGS vs XERS Comparison
PRGS vs XERS Comparison
Compare PRGS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGS | XERS |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRGS | XERS |
|---|---|---|
| Price | $39.08 | $10.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $56.20 | $12.86 |
| AVG Volume (30 Days) | 534.4K | ★ 2.3M |
| Earning Date | 09-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.79 | ★ 100.00 |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $397,572,000.00 | $49,590,000.00 |
| Revenue This Year | $7.13 | $32.91 |
| Revenue Next Year | $22.19 | $23.75 |
| P/E Ratio | $24.23 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $23.82 | $5.25 |
| 52 Week High | $47.25 | $10.35 |
Technical Indicators
Market Signals| Indicator | PRGS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 70.31 |
| Support Level | $35.97 | $7.15 |
| Resistance Level | $41.31 | N/A |
| Average True Range (ATR) | 1.71 | 0.53 |
| MACD | -0.05 | 0.13 |
| Stochastic Oscillator | 48.70 | 96.50 |
Price Performance
Historical ComparisonAbout PRGS Progress Software Corporation (DE)
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.